83004-10-8Relevant articles and documents
Ruthenium complexes bearing unsymmetric CNC' pincer ligands: Molecular structures and electronic properties
Naziruddin, Abbas Raja,Kuo, Chia-Liang,Lin, Wan-Jung,Lo, Wei-Hao,Lee, Chen-Shiang,Sun, Bian-Jian,Chang, A. Hsiu Hwa,Hwang, Wen-Shu
, p. 2575 - 2582 (2014)
Homoleptic ruthenium complexes [Ru(Ln)2]2+ bearing unsymmetric pyridine-based bis N-heterocyclic carbene (NHC) pincer ligands are synthesized and structurally characterized. These complexes feature the coexistence of a five-membered and a six-membered ruthenacycle within the same ligand framework, allowing an ideally octahedral CNHC-Ru-N Py bite angle close to 90°. In the solid state, impressive 3MLCT lifetimes of microsecond regime were detected in all of the complexes, of which [Ru(L4)2]2+, featuring four benzimidazol-2-ylidene donors, exhibited the longest values. Electronic properties of all of the ruthenium complexes are investigated by cyclic voltammetry and spectroscopic techniques. Density functional theory results were used to support the experimental observations.
Ruthenium complexes bearing N-heterocyclic carbene based CNC and CN^CH2C’ pincer ligands: Photophysics, electrochemistry, and solar energy conversion
Devan, Rupesh S.,Jain, Nimisha,Jose, D. Amilan,Manjunath, Vishesh,Mary, Angelina,Naziruddin, Abbas Raja,Sakla, Rahul
supporting information, (2021/12/17)
A combination of N-heterocyclic carbene (NHC) based CNC, or CN^CH2C′ pincer ligands and carboxy-phenyl terpyridine donors is used to prepare ruthenium complexes. The unsymmetrical coordination of CN^CH2C′ pincer
TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
-
Page/Page column 93-94, (2019/08/26)
The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF
-
Paragraph 0246; 0252; 0320-0323, (2019/07/03)
The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.